Amicus Therapeutics Inc [NASDAQ: FOLD] gained 0.53% or 4889994.34 points to close at $4890000.0 with a heavy trading volume of 4149292 shares.
It opened the trading session at $5.7, the shares rose to $5.7799 and dropped to $5.56, the range by which the price of stock traded the whole day. The daily chart for FOLD points out that the company has recorded -41.94% loss over the past six months.
If we look at the average trading volume of 4.89M shares, FOLD reached to a volume of 4149292 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Amicus Therapeutics Inc [FOLD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $16.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.36. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on December 13, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on September 06, 2024, representing the official price target for Amicus Therapeutics Inc stock. Previously, the target price had yet another raise to $18, while Wells Fargo analysts kept a Overweight rating on FOLD stock.
The Price to Book ratio for the last quarter was 9.05, with the Price to Cash per share for the same quarter was set at 0.81. Price to Free Cash Flow for FOLD in the course of the last twelve months was 1088.28 with Quick ratio for the last quarter at 2.47.
Trading performance analysis for FOLD stock
Amicus Therapeutics Inc [FOLD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.70. With this latest performance, FOLD shares dropped by -8.81% in over the last four-week period, additionally sinking by -41.94% over the last 6 months – not to mention a drop of -39.60% in the past year of trading.
Amicus Therapeutics Inc [FOLD]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Amicus Therapeutics Inc [FOLD] shares currently have an operating margin of 8.80% and a Gross Margin at 89.08%. Amicus Therapeutics Inc’s Net Margin is presently recorded at -5.41%.
Return on Equity for this stock declined to -3.89%, with Return on Assets sitting at -3.89%.
An analysis of Institutional ownership at Amicus Therapeutics Inc [FOLD]
There are presently around $102.83%, or 103.60% of FOLD stock, in the hands of institutional investors. The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 28.59 million shares, which is approximately 9.4111%. PERCEPTIVE ADVISORS LLC, holding 28.06 million shares of the stock with an approximate value of $$278.33 million in FOLD stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$271.81 million in FOLD stock with ownership which is approximately 9.0199%.
